CITIUS ONCOLOGY, INC. — Investor Relations & Filings
Filings indexed
224
across all filing types
Latest filing
2026-04-28
Regulatory Filings
Country
US
United States of America
Listing
US
CTOR
Citius Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative targeted oncology therapies. Its lead product, LYMPHIR™ (denileukin diftitox-cxdl), is a targeted immune therapy approved by the U.S. Food and Drug Administration (FDA) in August 2024. LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company's strategy involves expediting development pathways for treatments with reduced clinical risks and securing competitive advantages through intellectual property and regulatory exclusivity. Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, Inc.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer) | 2026-04-28 | English | |
| 8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer) | 2026-03-04 | English | |
| SCHEDULE 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject) | 2026-02-18 | English | |
| 10-Q Filing | 2026-02-13 | English | |
| 8-K Filing | 2026-02-13 | English | |
| PRELIMINARY INFORMATION STATEMENT | 2026-01-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 38179372 | 8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer) | 2026-04-28 | English | ||
| 32899802 | 8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer) | 2026-03-04 | English | ||
| 30316598 | SCHEDULE 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject) | 2026-02-18 | English | ||
| 32066545 | 10-Q Filing | 2026-02-13 | English | ||
| 32066479 | 8-K Filing | 2026-02-13 | English | ||
| 13408272 | PRELIMINARY INFORMATION STATEMENT | 2026-01-20 | English | ||
| 13408273 | Regulatory Filings 2026 | 2026-01-13 | English | ||
| 13408274 | REGISTRATION STATEMENT | 2026-01-05 | English | ||
|
2025
7 filings
| |||||
| 13408275 | CURRENT REPORT | 2025-12-23 | English | ||
| 13408276 | ANNUAL REPORT | 2025-12-23 | English | ||
| 13408277 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13408278 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13408279 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13408280 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
| 13408281 | OWNERSHIP DOCUMENT | 2025-12-22 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
CITIUS ONCOLOGY, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33815/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33815 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33815 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33815 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33815}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CITIUS ONCOLOGY, INC. (id: 33815)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.